转运体基因多态性与肺癌化疗反应的相关性。
The association of transporter genes polymorphisms and lung cancer chemotherapy response.
机构信息
Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha, Hunan, P. R. China.
The Affiliated Cancer Hospital of XiangYa School of Medicine, Central South University, Changsha, Hunan, P. R. China.
出版信息
PLoS One. 2014 Mar 18;9(3):e91967. doi: 10.1371/journal.pone.0091967. eCollection 2014.
Lung cancer is one of the most common cancers and is the leading cause of death worldwide. Platinum-based chemotherapy is the main treatment method in lung cancer patients. Our previous studies indicated that single nucleotide polymorphisms (SNPs) in some transporter genes played important role in platinum-based chemotherapy efficacy. The aim of this study was to investigate the association of SNPs in transporter genes and platinum-based chemotherapy efficacy. The main polymorphisms on transporters OCT2, LRP, AQP2, AQP9 and TMEM205 genes were genotyped in 338 lung cancer patients. The rs195854 in genotypic model, rs896412 in genotypic and recessive models for all subjects showed significant association with chemotherapy response. In stratification analysis, TMEM205 rs896412, OCT2 rs1869641 and rs195854, AQP9 rs1516400 and AQP2 rs7314734 showed significant relation to chemotherapy response. In conclusion, the genetic polymorphisms in OCT2, AQP2, AQP9 and TMEM205 may contribute to chemotherapy response in lung cancer patients.
肺癌是最常见的癌症之一，也是全球范围内导致死亡的主要原因。基于铂类的化疗是肺癌患者的主要治疗方法。我们之前的研究表明，一些转运体基因中的单核苷酸多态性（SNPs）在铂类化疗疗效中起着重要作用。本研究旨在探讨转运体基因中的 SNPs 与基于铂类的化疗疗效之间的关系。在 338 名肺癌患者中对转运体 OCT2、LRP、AQP2、AQP9 和 TMEM205 基因的主要多态性进行了基因分型。在所有受试者的基因型模型中 rs195854，基因型和隐性模型 rs896412 与化疗反应显著相关。在分层分析中，TMEM205 rs896412、OCT2 rs1869641 和 rs195854、AQP9 rs1516400 和 AQP2 rs7314734 与化疗反应显著相关。总之，OCT2、AQP2、AQP9 和 TMEM205 中的遗传多态性可能有助于肺癌患者的化疗反应。
Zotero 插件